Johnson & Johnson's financial report for July 4, 2021, outlines the company's financial position with total assets amounting to $176.4 billion and total liabilities and shareholders' equity also at $176.4 billion. They had $53.8 billion in current assets, comprising cash, marketable securities, accounts receivable, and inventories. The company's current liabilities stood at $38.7 billion, including loans and accounts payable. They reported net earnings of $6.3 billion for the fiscal second quarter of 2021, totaling $12.5 billion for the six months ended July 4, 2021. The report also details comprehensive income, equity, and cash flows. Additionally, it discusses operational highlights with segmented data on Consumer Health, Pharmaceutical, and Medical Devices branches, including earnings by segment, sales by geographic area, acquisitions, divestitures, and legal proceedings. The financial performance data reveals changes in earnings percentages, revenue by region, and specifics on internal financial transactions, acquisitions, and legal liabilities.
The provided text discusses various aspects of a company's financial performance, including sales data, analysis of financial condition, and results of operations. It highlights the sales growth in different segments such as Consumer Health, Pharmaceutical, and Medical Devices over fiscal periods. It details factors impacting operational sales growth, such as acquisitions/divestitures, currency fluctuations, and growth in different geographic regions. The document also delves into cost breakdowns, earnings before tax, cash flows, liquidity, capital resources, and potential impacts of certain factors like COVID-19, Brexit, tax laws, and intellectual property challenges on the company's financial position and operations. Moreover, it sheds light on restructuring charges, dividends, and other relevant economic factors affecting the business.
The text mentions that there has been no significant alteration in the company's evaluation of its susceptibility to market risk since it was last detailed in the Annual Report on Form 10-K for the fiscal year concluding on January 3, 2021.
The text discusses the evaluation of disclosure controls and procedures by a company's management, including its Chairman and Chief Executive Officer, and Executive Vice President, Chief Financial Officer. They concluded that the disclosure controls and procedures were effective at the end of the reporting period. Additionally, it mentions that there were no material changes in the company's internal controls over financial reporting during the same period, despite most employees working remotely due to the COVID-19 pandemic. The company actively refined its financial reporting process and monitoring controls to ensure accurate and timely reporting of financial results.
The text provided refers to the incorporation of information regarding legal proceedings into the financial statements through Note 11 in Part I, Item 1.
I'm ready to help you with the summary of the text now. Please provide me with the text you want me to summarize.
The provided text details the unregistered sales of equity securities and the use of proceeds by a company during the fiscal second quarter of 2021. The company made purchases of common stock on the open market as part of a systematic plan to address its compensation programs. A total of 3,791,600 shares of Johnson & Johnson Common Stock were repurchased during this quarter in various periods, with the shares bought at different average prices per share. The repurchases included stock-for-stock option exercises that were settled within the same period.
I'm sorry, but I cannot summarize without the text to reference. Please provide me with the text so that I can summarize it for you.
I'm sorry, but I cannot answer your request as there is no text provided for me to summarize. Please provide the text you would like me to summarize.
I'm sorry, but I cannot summarize the text for you as no text was provided. If you could please provide the text you would like me to summarize, I would be happy to assist you.
The text provides details on various exhibits filed with a document related to certifications required under the Sarbanes-Oxley Act of 2002. It includes certifications of the Chief Executive Officer and Chief Financial Officer under Rule 13a-14(a) and Section 302, as well as certifications under Section 906 of the Act. Additionally, it mentions various exhibits related to XBRL tags embedded within Inline XBRL documents. The document is signed on behalf of the registrant, Johnson & Johnson, by the Executive Vice President and the Controller.
